Study of safety and feasibility of personalized radiotherapy

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Data is not saved in preview.
"Personalized radiotherapy with four-dimensional (4D) computed tomography (CT)-based pulmonary ventilation imaging to treat lung cancer"
18 to 80 years old
Healthy Volunteers:
radiation, radiotherapy, lung cancer, cancer
Radiation study
This study will assess the safety and feasibility of personalized radiotherapy with four-dimensional (4D) computed tomography (CT)-based pulmonary ventilation imaging, which selectively avoids irradiating highly-functional lung regions.
This study requires

History and Physical Blood tests Respiratory tests CT Scans Radiotherapy

Who can participate

Inclusion Criteria:

  • Primary lung cancer or metastatic disease to the lungs to be treated with either conventionally-fractionated radiotherapy (CFRT) or hypo-fractionated stereotactic ablative radiotherapy (SABR).

  • Age restriction and/or gender/ethnic restrictions: Patients must be ≥18 years of age. There are no gender or ethnic restrictions.

  • Concurrent chemotherapy is allowed, but not required.

  • Life expectancy with treatment should be ≥6 months in the estimation of the treating physicians.

  • Zubrod performance status ≤2

  • Adequate marrow and hepatic function defined as Hgb ≥8; platelets ≥100k; ANC≥1500; LFTs ≤2x upper limit of normal and creatinine ≤1.3 or creatinine clearance of ≥50

  • Patient must be able to provide study specific informed consent prior to study entry.

Exclusion Criteria:

  • Prior radiotherapy for thoracic cancer or other malignancy leading to any overlap of planned radiotherapy fields.

  • For patients undergoing definitive CFRT, patients with distant metastatic disease are not eligible.

  • For patients undergoing SABR, both early stage primary lung cancer patients and those with limited metastatic disease to the lungs are eligible; however, patients with oligometastatic disease should have a controlled primary and no more than one other involved organ system.

  • Children (<18 years of age), pregnant women, University of California employees or students, or prisoners will be excluded from this study.

Study duration and period
Study treatment and procedures: 3-8 weeks Follow up: every 3 months for 2 years
Recruitment period
From Aug. 27, 2013
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Heather Melanson
Research Topic
  • Lung Cancer

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:

E-mail Preview